Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428661 · ClinicalTrials.gov registry record · Phase 2
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 507
- Enrollment target
NCT01428661 is a Phase 2 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 507 participants.
The verdict
NCT01428661, a Phase 2 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 507 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
Interventions
- DRUG placebo
- DRUG tasimelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428661
The ClinicalTrials.gov registry entry for NCT01428661 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01428661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01428661 about?
NCT01428661 is a clinical study titled "Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder". The purpose of this study is to evaluate the safety and efficacy of an 8-week double-masked treatment of tasimelteon or placebo in male and female subjects with Major Depressive Disorder.
What is the current status of trial NCT01428661?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 507 participants. The study started on 2011-09. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01428661?
The interventions under investigation include: placebo (DRUG), tasimelteon (DRUG).
Who is sponsoring clinical trial NCT01428661?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.